Skip to main content
OpenTrials
Completed

NCT Number: NCT00847860

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions

The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk factors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vascular Dementia Arterial Occlusive Diseases Arteriosclerosis Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Dementia Dementia, Vascular Intracranial Arterial Diseases Intracranial Arteriosclerosis Leukoencephalopathies Mental Disorders Nervous System Diseases Neurocognitive Disorders Stroke Vascular Diseases

Age range

40 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Peking University First Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ranging from 40 to 80 years
  • After newly ischemic stroke from 3 months to 2 years
  • Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC(Age Related White Matter Change)>=4
  • Moderate or mild cognitive deficits: MMSE 12-26
  • Vascular or mixed dementia: Hachinski ischemic score>4
  • Moderate or mild disability: MRS<=4,NIHSS<20
  • Informed consent

Exclusion criteria

  • Definitive diagnosis of dementia prior to the stroke
  • Cerebral hemorrhage in the past
  • Cerebral embolism result from cardiogenic embolus
  • Critically ills: MRS>4,NIHSS>=20
  • Bed-ridden patient who is hardly discovered newly stroke
  • patient with sever cardiac, hepatic or nephric complication
  • dementia caused not by vascular lesions
  • other diseases disturb the cognitive evaluation
  • susceptibility to varieties of allergen
  • abstain from Cilostazol or Asprin
  • antiplatelet treatment, anticoagulation or fibrinolysis are needed because of other diseases
  • rejected to participate by the patient or the family

Treatment and study plan

Cilostazol

Drug

Cilostazol 100 mg bid for 12 months

Aspirin

Drug

Aspirin 100 mg qd for 12 months

Primary outcomes

  1. changes of the scores of MMSE, MOCA,CDR,and Blessed-Roth

    Time frame: one year

Secondary outcomes

  1. stroke recurrence, other vascular ischemic events, bleeding events

    Time frame: one year

Sponsors and collaborators

Lead sponsor

Peking University First Hospital

Other

Collaborators

  • Zhejiang Otsuka Pharmaceutical Co., Ltd.

Registry information

Official study title

Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White

Acronym: CAVAD

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
Feb 19, 2009
Registry last updated
May 6, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.